Dupilumab efficacy and safety in patients with moderate to severe asthma: A systematic review and meta-analysis

Background: Dupilumab is a human monoclonal antibody directed against the alpha subunit of the interleukin-4 receptor and inhibits the signaling of IL-4 and IL-13. It is approved for treating asthma and other type-2 inflammatory diseases. There is a conflict in the literature regarding the safety an...

Descripción completa

Detalles Bibliográficos
Autores principales: Zaazouee, Mohamed Sayed, Alwarraqi, Asmaa Gomaa, Mohammed, Yasmine Adel, Badheeb, Mohamed A., Farhat, Abdullah Mohamed, Eleyan, Mohammed, Morad, Afnan, Zeid, Marwa Abdel-Aziz, Mohamed, Aya Shaban, AbuEl-Enien, Hazem, Abdelalim, Ahmed, Elsnhory, Ahmed Bostamy, Hrizat, Yasmin S. M., Altahir, Nagat Taha, Atef, Doaa, Elshanbary, Alaa Ahmed, Alsharif, Khalaf F., Alzahrani, Khalid J., Algahtani, Mohammad, Theyab, Abdulrahman, Hawsawi, Yousef M., Aldarmahi, Ahmed A., Abdel-Daim, Mohamed M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574251/
https://www.ncbi.nlm.nih.gov/pubmed/36263132
http://dx.doi.org/10.3389/fphar.2022.992731

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9574251/
https://www.ncbi.nlm.nih.gov/pubmed/36263132
http://dx.doi.org/10.3389/fphar.2022.992731

Ejemplares similares